Cell therapy CDMO services from development to commercial.

Contact Info
ul. Dzialkowa 85, 02-234 Warsaw, Poland info@bramble.bio  +44 7796354 376

News

Home > News & Events > News

Bramble Bio and Keli Therapeutics Announce Manufacturing Partnership to Advance New Cell Therapy for Acute Kidney Injury

25 Sep 2025 – Bramble Bio today announced a strategic manufacturing partnership with Keli Therapeutics to advance KELI-101, a novel cell therapy targeting acute kidney injury (AKI) following cardiac bypass surgery (CPB-AKI). This serious inflammatory complication often progresses to chronic kidney disease, leaving patients with limited treatment options. By pairing Keli’s breakthrough therapy with Bramble […]

Simon Boa 2025-09-25
Read More

BIONCaRT Announces Key Manufacturing Partnerships with Bramble Bio and Fraunhofer IZI to Support MesemCart Allogeneic Cell Therapy Clinical Trial

LEIPZIG, GERMANY – July 29, 2025 – BIONCaRT GmbH, a biotech company focused on developing cell therapies for orthopedic diseases, today announced strategic collaborations with Bramble Bio, a Contract Development and Manufacturing Organization (CDMO) specializing in cell and gene therapies and part of the FamiCord AG, and the Fraunhofer Institute for Cell Therapy and Immunology […]

Simon Boa 2025-07-28
Read More

Famicord Cell and Gene Manufacturing rebrands as Bramble Bio

Famicord AG (V3V) is rebranding its Contract Development and Manufacturing subsidiary, Famicord Cell and Gene Manufacturing, to Bramble Bio. This strategic move reflects the company’s commitment to innovation and growth in the field of novel cell therapies. “A core element of Famicord’s vision is to enhance access to cell therapies; Bramble Bio provides development services […]

empressia 2025-01-17
Read More